Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T)

UCI-07-40
NCT00585195
Cancer - Kidney, Cancer - Liver, Cancer - Lung, Cancer - Non-Hodgkin's Lymphoma, Cancer - Other Digestive Organ, Cancer - Soft Tissue, Cancer - Stomach, Cancer - Unknown Sites
Sai-Hong Ignatius Ou
Open
Treatment
Crizotinib, PF-02341066
Chemotherapy single agent systemic
I
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.